Johnson & Johnson (JNJ) - Total Liabilities
Based on the latest financial reports, Johnson & Johnson (JNJ) has total liabilities worth $113.54 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Johnson & Johnson cash flow conversion to assess how effectively this company generates cash.
Johnson & Johnson - Total Liabilities Trend (1985–2024)
This chart illustrates how Johnson & Johnson's total liabilities have evolved over time, based on quarterly financial data. Check Johnson & Johnson liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Johnson & Johnson Competitors by Total Liabilities
The table below lists competitors of Johnson & Johnson ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Berkshire Hathaway Inc
NYSE:BRK-B
|
USA | $525.52 Billion |
|
Exxon Mobil Corp
NYSE:XOM
|
USA | $182.35 Billion |
|
Tencent Holdings Ltd
F:NNND
|
Germany | €810.46 Billion |
|
Visa Inc. Class A
NYSE:V
|
USA | $58.04 Billion |
|
ASML Holding NV ADR
NASDAQ:ASML
|
USA | $30.94 Billion |
|
Tencent Holdings Ltd ADR
F:NNN1
|
Germany | €810.46 Billion |
|
SK Hynix Inc
KO:000660
|
Korea | ₩48.43 Trillion |
|
ASML Holding N.V.
AS:ASML
|
Netherlands | €30.95 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Johnson & Johnson's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Johnson & Johnson market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.10 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Johnson & Johnson's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Johnson & Johnson (1985–2024)
The table below shows the annual total liabilities of Johnson & Johnson from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $108.61 Billion | +9.95% |
| 2023-12-31 | $98.78 Billion | -10.66% |
| 2022-12-31 | $110.57 Billion | +2.39% |
| 2021-12-31 | $108.00 Billion | -3.24% |
| 2020-12-31 | $111.62 Billion | +13.60% |
| 2019-12-31 | $98.26 Billion | +5.42% |
| 2018-12-31 | $93.20 Billion | -4.06% |
| 2017-12-31 | $97.14 Billion | +37.23% |
| 2016-12-31 | $70.79 Billion | +13.70% |
| 2015-12-31 | $62.26 Billion | +1.46% |
| 2014-12-31 | $61.37 Billion | +4.67% |
| 2013-12-31 | $58.63 Billion | +3.73% |
| 2012-12-31 | $56.52 Billion | -0.08% |
| 2011-12-31 | $56.56 Billion | +22.09% |
| 2010-12-31 | $46.33 Billion | +5.07% |
| 2009-12-31 | $44.09 Billion | +3.99% |
| 2008-12-31 | $42.40 Billion | +12.66% |
| 2007-12-31 | $37.63 Billion | +20.48% |
| 2006-12-31 | $31.24 Billion | +55.00% |
| 2005-12-31 | $20.15 Billion | -6.28% |
| 2004-12-31 | $21.50 Billion | +0.51% |
| 2003-12-31 | $21.39 Billion | +19.79% |
| 2002-12-31 | $17.86 Billion | +25.28% |
| 2001-12-31 | $14.26 Billion | +2.92% |
| 2000-12-31 | $13.85 Billion | +6.95% |
| 1999-12-31 | $12.95 Billion | -2.01% |
| 1998-12-31 | $13.21 Billion | +45.32% |
| 1997-12-31 | $9.09 Billion | -0.87% |
| 1996-12-31 | $9.17 Billion | +3.92% |
| 1995-12-31 | $8.83 Billion | +3.30% |
| 1994-12-31 | $8.55 Billion | +28.05% |
| 1993-12-31 | $6.67 Billion | -0.58% |
| 1992-12-31 | $6.71 Billion | +37.36% |
| 1991-12-31 | $4.89 Billion | +6.10% |
| 1990-12-31 | $4.61 Billion | +22.14% |
| 1989-12-31 | $3.77 Billion | +4.29% |
| 1988-12-31 | $3.62 Billion | +18.13% |
| 1987-12-31 | $3.06 Billion | +0.28% |
| 1986-12-31 | $3.05 Billion | +75.01% |
| 1985-12-31 | $1.74 Billion | -- |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more